You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia
|
|---|---|
| Published in |
Future Oncology, January 2016
|
| DOI | 10.2217/fon.15.326 |
| Pubmed ID | |
| Authors |
Gail J Roboz, Pau Montesinos, Dominik Selleslag, Andrew Wei, Jun-Ho Jang, Jose Falantes, Maria T Voso, Hamid Sayar, Kimmo Porkka, Paula Marlton, Antonio Almeida, Sanjay Mohan, Farhad Ravandi, Guillermo Garcia-Manero, Barry Skikne, Hagop Kantarjian |
| Abstract |
Older patients with acute myeloid leukemia (AML) have worse rates of complete remission and shorter overall survival than younger patients. The epigenetic modifier CC-486 is an oral formulation of azacitidine with promising clinical activity in patients with AML in Phase I studies. The Phase III, randomized, double-blind, placebo-controlled QUAZAR AML Maintenance trial (CC-486-AML-001) examines CC-486 maintenance therapy (300 mg/day for 14 days of 28-day treatment cycles) for patients aged ≥55 years with AML in first complete remission. The primary end point is overall survival. Secondary end points include relapse-free survival, safety, health-related quality of life and healthcare resource utilization. This trial will investigate whether CC-486 maintenance can prolong remission and improve survival for older patients with AML. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | 25% |
| Unknown | 3 | 75% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 76 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Finland | 1 | 1% |
| Peru | 1 | 1% |
| Unknown | 74 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 15 | 20% |
| Other | 9 | 12% |
| Student > Bachelor | 9 | 12% |
| Student > Master | 9 | 12% |
| Student > Doctoral Student | 7 | 9% |
| Other | 12 | 16% |
| Unknown | 15 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 38 | 50% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
| Biochemistry, Genetics and Molecular Biology | 3 | 4% |
| Nursing and Health Professions | 3 | 4% |
| Agricultural and Biological Sciences | 3 | 4% |
| Other | 7 | 9% |
| Unknown | 18 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 January 2022.
All research outputs
#6,725,788
of 25,837,817 outputs
Outputs from Future Oncology
#584
of 2,258 outputs
Outputs of similar age
#97,434
of 407,196 outputs
Outputs of similar age from Future Oncology
#10
of 47 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 2,258 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 407,196 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 47 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.